Virtu KCG Holdings’s ProQR Therapeutics PRQR Stock Holding History

Virtu KCG Holdings’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,367	Closed	-$52K	–	3358
2017 Q1	$52K	Buy	+10,367	New	+$45.6K	﹤0.01%	2840

Other funds holding PRQR

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Virtu KCG Holdings's PRQR Position: Q2 2017 in Review

Virtu KCG Holdings sold out of ProQR Therapeutics (PRQR) in Q2 2017, closing a stake of 10,367 shares — an estimated $52K sold.

Virtu KCG Holdings first reported a position in PRQR in Q1 2017 and held it in 1 quarter. The position peaked at $52K in Q1 2017. 18 funds tracked by Wall St. Rank hold PRQR as of Q2 2017.

Virtu KCG Holdings reported no remaining ProQR Therapeutics position as of Q2 2017 after selling out during the quarter.
Virtu KCG Holdings sold 10,367 ProQR Therapeutics shares in Q2 2017, an estimated $52K.
Virtu KCG Holdings first reported a position in ProQR Therapeutics in Q1 2017 and held it in 1 quarter.
Virtu KCG Holdings's ProQR Therapeutics position peaked at $52K in Q1 2017.
18 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.